La cadena de opciones muestra datos clave de las opciones de acciones de Docusign a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Docusign..

Docusign (NASDAQ:DOCU) Bolsa, Cadena de Opciones

DOCUSIGN INC

DocuSign

Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.

Docusign

Lululemon

Equities

DOCU

GIII

LULU

MANU

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: ABM, DOCU, GIII, LULU y MANU.

5 acciones en el foco este viernes: ABM, DOCU, GIII, LULU y MANU

DocuSign.How-it-Works_2020_thumb_Update

News

Movers

DocuSign sorprende con un sólido informe financiero y una nueva plataforma de IA. Analistas ajustan sus pronósticos.

Acciones de DocuSign (DOCU) suben un 17,9% tras superar expectativas: ¿seguirá la tendencia alcista?

Movers_Stocks

AAOI

AFYA

AKBA

BTBT

CVNA

FUTU

GDOT

QBTS

RBRK

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech sorprendió al mercado con ingresos y ganancias superiores a lo esperado. Inversores reaccionan ante este sólido desempeño trimestral.

Semtech, Rubrik, DocuSign, PagerDuty y otras acciones estadounidenses que suben el viernes

Keybanc analyst Aleksey Yefremov maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Overweight and raises the price target from $53 to $61.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on FMC, Raises Price Target to $61

Barclays analyst Saket Kalia maintains Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) with a Overweight and raises the price target from $43 to $51.

HNGE

Barclays Maintains Overweight on Hinge Health, Raises Price Target to $51

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst Joe Vruwink upgraded the rating for nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) from Neutral to Outperform and raised the price target from $30 to $38. Ncino shares closed at $28.82 on Friday. <a href="https://www.benzinga.com/quote/ncno/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Jeff Cantwell upgraded Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) from Neutral to Buy and maintained the price target of $616. Mastercard shares closed at $550.18 on Friday. <a href="https://www.benzinga.com/quote/ma/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Robert Moskow upgraded the rating for WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) from Sell to Hold and raised the price target from $14 to $23. WK Kellogg shares closed at $22.89 on Friday. <a href="https://www.benzinga.com/quote/klg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Joseph Spak upgraded Visteon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Neutral to Buy and raised the price target from $85 to $142. Visteon shares closed at $110.73 on Friday. <a href="https://www.benzinga.com/quote/vc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Ralph Schackart upgraded the rating for Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) from Market Perform to Outperform. Stitch Fix shares closed at $3.94 on Friday. <a href="https://www.benzinga.com/quote/sfix/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-1024x582.png" alt="" class="wp-image-983887" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46388321/top-3-health-care-stocks-that-could-blast-off-in-july">Top 3 Health Care Stocks That Could Blast Off In July</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

NCNO

SFIX

This Mastercard Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

WIIM

DGNX

Diginex shares are trading lower after the company reported FY25 financial results.

Keybanc analyst Aleksey Yefremov maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Overweight and raises the price target from $28 to $29.

Keybanc Maintains Overweight on Element Solutions, Raises Price Target to $29

Keybanc analyst Aleksey Yefremov maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Overweight and lowers the price target from $117 to $112.

ENTG

Keybanc Maintains Overweight on Entegris, Lowers Price Target to $112

DEFT

Defi Technologies shares are trading higher after the company provided Bitcoin assets under management updates for its subsidiary, Valour.

Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)&nbsp;has agreed to combine its Biosciences &amp; Diagnostic Solutions business with Waters Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>).
The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. The transaction is expected to close around the end of the first quarter of calendar year 2026.
<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Biosciences segment</a> offers immunology and cancer research solutions and related clinical diagnostics, including flow cytometry instruments, reagents, and multiomics tools.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/05/45179007/becton-dickinson-vitals-drop-analysts-have-been-wrong-on-this-med-tech-stock-for-years" target="_blank" rel="noreferrer noopener">Becton Dickinson Vitals Drop: Analysts &#8216;Have Been Wrong&#8217; On This Med Tech Stock For Years</a>
Diagnostic Solutions offers microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, microbiology automation, and point-of-care offerings.
For calendar year 2025, BD&#8217;s Biosciences &amp; Diagnostic Solutions business is expected to generate revenue of approximately&nbsp;$3.4 billion&nbsp;and adjusted EBITDA of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46387499/waters-and-bds-biosciences-diagnostic-solutions-business-to-combine-creating-a-life-science-and-di" rel="noreferrer noopener">approximately&nbsp;$925 million</a>.
<h2 class="wp-block-heading">Financial Benefits</h2>
The transaction is expected to create approximately&nbsp;$200 million&nbsp;of cost synergies by year three post-closing, and approximately&nbsp;$290 million&nbsp;of revenue synergies by year five, resulting in approximately&nbsp;$345 million&nbsp;of annualized EBITDA synergies by 2030.
Cost synergies are expected to be driven primarily by manufacturing, supply chain, and SG&amp;A optimization while maintaining a strong commitment to R&amp;D and commercial investments.
Revenue synergies are expected from commercial excellence, accelerating expansion into high-growth adjacencies, and realizing cross-selling opportunities.
The combined company is expected to generate pro forma revenue of approximately&nbsp;$6.5 billion&nbsp;and approximately&nbsp;$2.0 billion&nbsp;in pro forma adjusted EBITDA for calendar year 2025.
On a pro forma basis, the combination is expected to deliver mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth on an annualized basis between 2025 and 2030.
By 2030, the pro forma combined company is expected to have an industry-leading financial outlook with approximately&nbsp;$9 billion&nbsp;in revenue,&nbsp;$3.3 billion&nbsp;in adjusted EBITDA, and an adjusted operating margin of 32%.
The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
Commenting on the transaction, Flemming Ornskov, Chairman, Waters, said, &#8220;This transaction marks a pivotal milestone in Waters&#8217; transformation journey as we embark on a new chapter of growth and value creation. As the Board of Directors evaluated this opportunity throughout the process, it became evident that combining with BD&#8217;s Biosciences &amp; Diagnostic Solutions business is an excellent strategic fit with complementary strengths. We are confident that this combination will accelerate our strategy in multiple high-growth markets and deliver substantial near- and long-term value to our shareholders.&#8221;
BD&#8217;s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8%. BD will also receive a cash distribution of approximately $4 billion before completion of the combination.
Waters is expected to assume approximately&nbsp;$4 billion&nbsp;of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing.
Price Action: WAT stock was down 5.07% at $335, and BDX stock was down 0.84% at $174.50 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46386582/elon-musk-wants-tesla-to-invest-in-xai-but-its-up-to-shareholders-this-analyst-says-grok-is-worth-the-bet" target="_blank" rel="noreferrer noopener">Elon Musk Wants Tesla To Invest In xAI, But It&#8217;s Up To Shareholders: This Analyst Says Grok Is Worth The Bet</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

General

Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger

VBTX

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Keybanc analyst Scott Schoenhaus maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and lowers the price target from $106 to $93.

Keybanc Maintains Overweight on Eastman Chemical, Lowers Price Target to $93

Barclays analyst Saket Kalia maintains Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) with a Equal-Weight and raises the price target from $30 to $32.

Barclays Maintains Equal-Weight on Gen Digital, Raises Price Target to $32

SQNS

Sequans shares are trading higher after the company announced it bought 683 more Bitcoins and provided updates on its total holdings.

Keybanc analyst Scott Schoenhaus maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Overweight and raises the price target from $65 to $70.

DOCS

Keybanc Maintains Overweight on Doximity, Raises Price Target to $70

NCino shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $30 to $38.

Keybanc analyst Aleksey Yefremov maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $85 to $87.

Keybanc Maintains Overweight on DuPont de Nemours, Raises Price Target to $87

Barclays analyst Saket Kalia maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Equal-Weight and raises the price target from $103 to $110.

FTNT

Barclays Maintains Equal-Weight on Fortinet, Raises Price Target to $110

CRWD

CrowdStrike Holdings shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.

Cryptocurrency markets are off to a blazing start on Monday morning, with Bitcoin making a new all-time high above $123,000.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$121,812.36</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,070.88</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$167.48</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.99</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2069</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001383</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction decreased by 14.7% and 7.9%, respectively. Daily active addresses dropped by 5.6% and 3.6%, respectively.</li>
<li>Coinglass data shows129,769 traders were liquidated in the past 24 hours for $750.05 million.</li>
<li>SoSoValue data shows net inflows of $1.03 billion into spot Bitcoin ETFs on Friday. Spot Ethereum ETFs saw net inflows of $204.8 million.</li>
</ul>
Trader Notes: CoinBureau co-founder Nic Puckrin <a href="https://x.com/nicrypto/status/1944645969556963392">highlighted</a> the importance of Bitcoin breaching a 7-year-long monthly resistance trendline, which acted as the ceiling in past bull markets dating back to 2018.
Rekt Capital <a href="https://x.com/rektcapital/status/1944697759107281211">says</a> a convincing breakout above $124,000 would open the floodgates for Bitcoin, triggering rapid price discovery with little resistance above.
Michael van de Poppe forecasts rising volatility, with sharp dips likely to be absorbed quickly. He believes the next major leg to $250,000 has begun, projecting $150,000 by Q3.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There we go. A massive impulse on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> as it&#39;s at $122K. What to expect? Volatility has been going up, so we will be having severe corrections which are going to be quickly bought up. The upwards move to $250K has started. $150K in Q3. <a href="https://t.co/ixSbObm24u">pic.twitter.com/ixSbObm24u</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1944669726828826928?ref_src=twsrc%5Etfw">July 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cryptoinsightuk <a href="https://x.com/Cryptoinsightuk/status/1944688049851363545">explained</a> that a break above $3.00 for XRP could unlock a move to all-time highs and initiate price discovery. The current price action is pressing against the final major resistance.
Crypto trader Jelle <a href="https://x.com/CryptoJelleNL/status/1944642366998012320">noted</a> Ethereum finally broke above the $2,800 resistance, flipping it into support. With momentum now shifting upward, the next key target is $4,000, as minimal resistance remains in that zone.
Jelle <a href="https://x.com/CryptoJelleNL/status/1944676843077964034">shared</a> a bold outlook, stating $600 is the long-term target for SOL, as the broader market rally gains traction.
Crypto trader CW pointed out that DOGE has broken its first sell wall and is approaching the next resistance zone between $0.24–$0.26, signaling further upside potential.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> is breaking the first sell wall. The next sell wall is $0.24-$0.26. <a href="https://t.co/jIc0qVwbDf">pic.twitter.com/jIc0qVwbDf</a>
&mdash; CW (@CW8900) <a href="https://twitter.com/CW8900/status/1944638939899326683?ref_src=twsrc%5Etfw">July 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46387048/bitcoin-is-humanitys-best-bet-against-currency-debasement-says-anthony-pompliano-we-owe-so-much-to-satoshi-nakamoto">Bitcoin Is Humanity&#8217;s &#8216;Best Bet&#8217; Against Currency Debasement, Says Anthony Pompliano: &#8216;We Owe So Much To Satoshi Nakamoto&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Why Are Bitcoin, Ethereum, XRP, Dogecoin Suddenly Skyrocketing?

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fvsee.como&amp;esheet=54289531&amp;newsitemid=20250714034916&amp;lan=en-US&amp;anchor=VSee+Health%2C+Inc.&amp;index=1&amp;md5=589aac8d6e07e263f1a9587e1a62a9a5">VSee Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) a leading provider of secure digital health solutions, today announced the launch of its new AI doctor notes, one of the solutions in its AI solutions suite.
VSee has partnered with Tele911, the largest national telemedicine emergency room diversion service, to integrate VSee's AI Doctor Notes into its virtual emergency care workflow. Emergency medicine demands rapid decision-making and high patient throughput. The integration has drastically reduced Tele911 physician's charting time by 93% from 15 minutes per visit to under 1 minute, potentially increasing physician visit capacity.
This new VSee AI solution automatically transcribes visits and generates structured SOAP notes with ICD codes in two clicks, allowing Tele911 physicians to reclaim valuable time. Now, instead of manual documentation, clinicians can focus on patient care.

Biotech

VSEE

VSee Launches AI Doctor Notes, Cutting Tele911 Physician Charting Time By 93% From 15 Minutes Per Visit To Under 1 Minute, Boosting Emergency Care Efficiency

Barclays analyst Saket Kalia maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Overweight and raises the price target from $405 to $440.

CYBR

Barclays Maintains Overweight on CyberArk Software, Raises Price Target to $440

Press Releases

Identity Fraud Costs Organizations an Average of $7 Million Annually, Says New Research From Docusign and Entrust

Docusign tops Newsweek's list of the Most Trustworthy Software and Telecommunications Companies in America 2025

New Docusign Partner Program to Drive Business Success in the Era of Intelligent Agreement Management

Docusign Ushers in a New Era of AI Contract Agents to Transform Business

Cognizant Expands Partnership with Docusign to Enhance Customer Support and Drive Digital Transformation

Docusign Appoints Michael Adams as New Chief Information Security Officer

Docusign CLM Connector for Coupa Certified as Coupa Total Spend Management Platform Ready

Docusign Announces Timing of First Quarter Fiscal 2026 Earnings Conference Call

Earnings

Fintech

Docusign Announces First Quarter Fiscal 2026 Financial Results; Announces $1.0 Billion Increase to Share Repurchase Program

Docusign launching six personality-packed signature styles for ESIGN Act's 25th anniversary

Comments

Docusign

Docusign (DOCU) Opciones

Docusign (NASDAQ:DOCU) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL